Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2009
05/21/2009US20090131437 Disubstituted ureas as kinase inhibitors
05/21/2009US20090131436 Pyrimidine Derivatives
05/21/2009US20090131435 Heterocyclic inhibitors of mek and methods of use
05/21/2009US20090131434 such as E-4-[(2-methyl-2-{[4-(trifluoromethyl)benzyl]oxy}propanoyl)amino]adamantane-1-carboxamide, used for the treatment of non-insulin dependent diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, dementia, psychosis, depression or anxiety
05/21/2009US20090131433 such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders
05/21/2009US20090131432 type II diabetes mellitus and obesity; dipeptidylpeptidase-IV (DPP-IV) inhibitor; 1-[2-(2-formylaminophenyl)-2-oxoethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine (xanthine=3,7-dihydro-purine-2,6-dione)
05/21/2009US20090131431 Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
05/21/2009US20090131430 Pyrido'2,3-dipyrimidines as anti-inflammatory agents
05/21/2009US20090131429 Pharmaceutical compounds
05/21/2009US20090131428 Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
05/21/2009US20090131427 treating autoimmune disease, cancer, or atherosclerosis; inhibiting TNF alpha expression, IL-1 beta expression, iNOS expression, and NF- kappa B activity; (3aR,6Z,10E,11aR) N,10-dimethyl-3-methylene-2-oxo-2,3,3a,4,5,8,9,11a-octahydrocyclodeca[b]furan-6-carboxamide
05/21/2009US20090131426 Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-urea, compositions thereof, and uses therewith
05/21/2009US20090131425 Inhibitors of protein kinases
05/21/2009US20090131424 Thiazolyl-dihydro-chinazoline
05/21/2009US20090131423 Tyrosine Kinase Inhibitors
05/21/2009US20090131422 Salts of an IKK inhibitor
05/21/2009US20090131421 Compounds for proteasome enzyme inhibition
05/21/2009US20090131420 Novel Heterocyclic Analogs of Biphenyl Ethers
05/21/2009US20090131419 Which modulates activity of amyloid precursor proteins; Alzheimer's disease
05/21/2009US20090131418 Spiroazacyclic compounds as monoamine receptor modulators
05/21/2009US20090131417 Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
05/21/2009US20090131416 Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor
05/21/2009US20090131415 Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
05/21/2009US20090131414 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
05/21/2009US20090131413 Thienopyrazole Derivative Having PDE7 Inhibitory Activity
05/21/2009US20090131412 Novel 2-quinolone derivative
05/21/2009US20090131411 monoamidino-containing compounds having good bioavailability and/or solubility, used as potent and specific inhibitors of blood coagulation in mammals, and as therapeutic agents for disease states characterized by coagulation disorders
05/21/2009US20090131410 3-azabicyclooctane derivatives as muscarinic receptor antagonists
05/21/2009US20090131409 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
05/21/2009US20090131408 Organic Compounds
05/21/2009US20090131407 Tetracyclic kinase inhibitors
05/21/2009US20090131406 Cropwelllins and synthetic derivatives thereof used as medicaments
05/21/2009US20090131405 Imidazoazepinone compounds
05/21/2009US20090131404 Combinations
05/21/2009US20090131403 Nitrogenated heterocyclic derivative , and pharmaceutical agent comprising the derivative as active ingredient
05/21/2009US20090131402 Fused heterocyclic compound and use thereof
05/21/2009US20090131401 Transcription factor modulating compounds and methods of use thereof
05/21/2009US20090131400 Immunosuppressant compounds and compositions
05/21/2009US20090131399 Imidazopyridine Derivatives Useful as iNOS Inhibitors
05/21/2009US20090131398 Oxindole derivative as feeding control agent
05/21/2009US20090131397 Estrogen modulators
05/21/2009US20090131396 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies
05/21/2009US20090131395 Biphenylazetidinone cholesterol absorption inhibitors
05/21/2009US20090131394 Broad spectrum beta-lactamase inhibitors
05/21/2009US20090131393 Process for Preparing Chlorides of Phthalocyanine Derivatives Comprising at Least a Quaternary Ammonium Group
05/21/2009US20090131392 Phtalocyanine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
05/21/2009US20090131391 Inhibitor for differentiation of hematopoietic precursor cells
05/21/2009US20090131390 FK 228 derivates as HDAC inhibitors
05/21/2009US20090131389 Preparation of a Crystalline Antibiotic Substance
05/21/2009US20090131388 Agent for Improving Insulin Resistance
05/21/2009US20090131387 Transdermal formulation containing androgen, macrocyclic ester or ketone enhancer and thickener; extended time high blood serum concentration; rapidly absorbed gel; treatment of male hypogonadism
05/21/2009US20090131386 Compositions for the treatment of inflammation of the gastrointestinal tract
05/21/2009US20090131385 Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
05/21/2009US20090131384 Compounds and methods for treatment of disorders associated with er stress
05/21/2009US20090131383 Pharmaceutical compositions of a neuroactive steriod and methods of use thereof
05/21/2009US20090131382 Treatment of rheumatoid arthritis using imatinib
05/21/2009US20090131381 Compositions comprising hydroquinone, fluocinolone acetonide and tretinoin for treating photoaging of the skin
05/21/2009US20090131380 Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
05/21/2009US20090131379 Vitamin d receptor activators and methods of making
05/21/2009US20090131378 Vitamin d derivatives active on the vitamin d nuclear receptor, preparation and uses thereof
05/21/2009US20090131377 Combinations of Superoxide Dismutase Mimetics and Nonsteroidal Analgesic/Anti-Inflammatory Drugs
05/21/2009US20090131376 Process for the modification of the solid state of a compound and co-amorphous compositions produced with same
05/21/2009US20090131375 Composition and method for treating skin
05/21/2009US20090131374 Protein tyrosine phosphatase inhibitors and methods of use thereof
05/21/2009US20090131373 Phospholipid complexes of curcumin having improved bioavailability
05/21/2009US20090131372 Phosphonate analogs for treating metabolic diseases
05/21/2009US20090131371 Novel phosphonic acid compounds as inhibitors of serine proteases
05/21/2009US20090131370 Novel Nucleoside Derivatives
05/21/2009US20090131369 Novel Benzimidazole(Thio)Carbamates with Antiparasitic Activity and the Synthesis Thereof
05/21/2009US20090131368 Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
05/21/2009US20090131367 Combinations of HDAC Inhibitors and Proteasome Inhibitors
05/21/2009US20090131366 Use of Amine-Borane Compounds as Anti-Microbial Agents
05/21/2009US20090131365 Novel heterocycle derivatives useful as selective androgen receptor modulators (sarms)
05/21/2009US20090131364 Bioactive fraction from zingier officinale and a process for the preparation thereof
05/21/2009US20090131363 Deuterated darunavir
05/21/2009US20090131362 Use of defibrotide for the inhibition of heparanase
05/21/2009US20090131361 Novel Use of MLN51 Gene and Protein
05/21/2009US20090131360 Tripartite RNAi constructs
05/21/2009US20090131358 LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
05/21/2009US20090131357 Compositions and methods for preventing and treating cancer via modulating UBE1L, ISG15 and/or UBP43
05/21/2009US20090131356 miR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292-3P REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
05/21/2009US20090131355 Multicistronic vectors and methods for their design
05/21/2009US20090131354 miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
05/21/2009US20090131353 Using cyclic nucleotide phosphodiesterase profiles as tool in detection of cell proliferative disorders
05/21/2009US20090131352 Aptamers comprising arabinose modified nucleotides
05/21/2009US20090131351 Methods, compositions, and kits for modulating tumor cell proliferation
05/21/2009US20090131350 Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor
05/21/2009US20090131349 Methods and Compositions for Modulating Body Weight and for Treating Weight Disorders and Related Diseases
05/21/2009US20090131348 Micrornas differentially expressed in pancreatic diseases and uses thereof
05/21/2009US20090131347 Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a th1 phenotype
05/21/2009US20090131346 Antibody and method for identification of dendritic cells
05/21/2009US20090131345 Medicament and method for treating recurrent spontaneous abortion
05/21/2009US20090131344 Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
05/21/2009US20090131343 Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
05/21/2009US20090131342 Nitrosated and/or nitrosylated compounds, compositions and methods of use
05/21/2009US20090131341 Novel Dihydropseudoerythromycin Derivatives
05/21/2009US20090131340 Use of flavonoids as immunomodulating or immuno-protective agents in cosmetic and dermatological preparations
05/21/2009US20090131339 Compounds having neuroprotective properties
05/21/2009US20090131338 Anesthesia arousal composition
05/21/2009US20090131336 Isoxazole Derivatives and Use Thereof
1 ... 2726 2727 2728 2729 2730 2731 2732 2733 2734 2735 2736 2737 2738 2739 2740 2741 2742 2743 2744 2745 2746 ... 7860